GLIX1

About Hemispherian

Hemispherian is pioneering a novel epigenetic approach to cancer therapy by developing small molecule activators of the TET2 enzyme. This 'first-in-class' mechanism aims to selectively restore the depleted DNA modification 5-hydroxymethylcytosine in cancer cells, inducing cytotoxicity while sparing normal tissues. The company's lead asset, GLIX1, is advancing into clinical trials for glioblastoma through a partnership with BioLineRx, with a broader pipeline, including GLIX5, in earlier stages. Backed by public Norwegian and European support, Hemispherian is targeting high-unmet-need oncology indications with a potentially safer and more effective therapeutic strategy.

About BioLineRx

BioLineRx is a publicly traded, Israeli biotech company with a mission to develop best-in-class therapies for oncology and rare diseases. Its core strategy involves in-licensing and advancing novel drug candidates through clinical proof-of-concept, exemplified by the successful FDA approval and out-licensing of its stem cell mobilizer, motixafortide (APHEXDA®). The company has now pivoted back to a lean development model, focusing its resources on a promising new joint venture for GLIX1 in glioblastoma and a partnered Phase 2b trial in pancreatic cancer.

Therapeutic Areas

Other Glioblastoma Drugs